1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for people in Mansfield who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Some centers and doctors are certified to administer specific meds to opioid dependent clients, many of which are opioids themselves and are addictive. With low enough doses however, the client does not experience high feelings but also does not experience intense cravings and is not in opioid withdrawal. Methadone is the first medication administered for this reason, but there are a few more choices to choose from.
Methadone is an opioid and is meant to be taken at an outpatient medical center licensed to dispense the drug, that is taken on a daily basis in liquid or pill form. The cost of the drug is about $150 monthly. Buprenorphine is also an opiate based drug, and is a pill often taken one day on, one day off. But different from Methadone that can only be dispensed in highly structured medical centers, Buprenorphine can be prescribed and administered in doctor's offices. The price monthly of buprenorphine is about $300.00 per month for the generic of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, that is a drug which reverses the effects of opioids. A person taking this version of the drug, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and costs approximately $450 a month. Naltrexone is an additional drug taken in opioid maintenance therapy, but unlike the other medications mentioned here it's an opiate blocker and isn't an opioid. There is an option to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 per month.
For All Drug and Alcohol Treatment Programs In Mansfield, Click Here.
